Kidney Week

Abstract: SA-PO701

The Irish Rituximab Study (IRiS): A Nationwide Study of Rituximab Prescribing and Effectiveness for the Treatment of Kidney Diseases

Session Information

• Glomerular Diseases: Clinical, Outcomes, Trials - III
  November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials

Authors

• Kelly, Dearbhla M., Beaumont Hospital, Dublin, Ireland

Dearbhla M. Kelly,

• Ni Cathain, Dearbhail, Beaumont Hospital, Dublin, Ireland

Dearbhail Ni Cathain,

• O'Connell, Blathnaid, University Hospital Waterford, Waterford, Waterford, Ireland

Blathnaid O'Connell,

• O'Hanlon, James, Beaumont Hospital, Dublin, Ireland

James O'Hanlon,

• Hanahoe, Aislinn Ellen, Tallaght University Hospital, Dublin, Dublin, Ireland

Aislinn Ellen Hanahoe,

• O'Brien, Sorcha, St. James's Hospital, Dublin, Ireland

Sorcha O'Brien,

• Ahmed, Omer, University Hospital Limerick, Dooradoyle, Limerick, Ireland

Omer Ahmed,

• Piggott, Raymond Simon, Mater Misericordiae University Hospital, Dublin, Ireland

Raymond Simon Piggott,

• Slattery, Laura M., Beaumont Hospital, Dublin, Ireland

Laura M. Slattery,

• White, Eoghan, Cork University Hospital, Cork, Cork, Ireland

Eoghan White,

• Brown, Catherine M., University Hospital Waterford, Waterford, Waterford, Ireland

Catherine M. Brown,

• Casserly, Liam F., University Hospital Limerick, Dooradoyle, Limerick, Ireland

Liam F. Casserly,

• Hudson, Amy, Beaumont Hospital, Dublin, Ireland

Amy Hudson,

• Little, Mark Alan, Tallaght University Hospital, Dublin, Dublin, Ireland

Mark Alan Little,

• Sadlier, Denise M., Mater Misericordiae University Hospital, Dublin, Ireland

Denise M. Sadlier,

• Sexton, Donal J., St. James's Hospital, Dublin, Ireland

Donal J. Sexton,

• Moran, Sarah Margaret, Cork University Hospital, Cork, Cork, Ireland

Sarah Margaret Moran,

• O'Shaughnessy, Michelle M., Cork University Hospital, Cork, Cork, Ireland

Michelle M. O'Shaughnessy,

• Conlon, Peter J., Beaumont Hospital, Dublin, Ireland

Peter J. Conlon,

Group or Team Name

• IRish Rituximab Study (IRiS)

Background

Rituximab is increasingly used to treat glomerular diseases, including ANCA-associated vasculitis (AAV), membranous nephropathy, minimal change disease (MCD), and focal segmental glomerulosclerosis (FSGS). However, strong evidence supporting its use in some of these conditions is lacking and it is also costly and potentially toxic. Using nationwide data, we examined prescribing practices and clinical outcomes in Irish patients who received Rituximab for glomerular disease.

Methods

All patients attending Irish Nephrology Centres who received Rituximab for glomerular disease between 01/01/13 and 31/12/21 were included in this retrospective observational study. Rituximab dosing, prior and concurrent medications, clinical presentation, and outcomes were extracted from electronic healthcare records. The primary efficacy outcome was complete or partial remission at 12 months. Descriptive statistics are herein presented.

Results

From 9 participating centres, we identified 405 patients (median age 55.3 years; 37.3% female), a majority (53%) of whom had AAV, Table. The most frequent Rituximab dose was 1g (60%) and the median cumulative dose received was 3g (IQR 2-4g). From patients with available outcome data (n=306), 259 (85%) achieved CR or PR by a median of 5 (IQR 2-10) months. During a median follow-up of 49 (IQR 31-74) months, 71 (23%) patients had disease relapses and 80 (25%) experienced adverse events: 72 (22%) infections, 40 (13%) leucopenia, 18 (9%) infusion reactions, 15 (7%) malignancies, and 12 (3%) episodes of hypogammaglobuinemia.

Conclusion

Based on preliminary data, Rituximab was an effective and safe treatment in the majority of Irish adults with glomerular disease who received it.